Florencia Healthcare
Florencia Healthcare
Gautam Budh Nagar, Uttar Pradesh
GST No. 09AACFF7918C1ZI
TrustSEAL Verified
Call 0804883796476% Response Rate
SEND EMAIL

Branded Oncology Products

We are a leading Manufacturer of fulvestrant injection 250mg, paclitaxel nanoparticle injection, trastuzumab for injection 440mg/150mg, nimotuzumab injection, pemetrexed for injection 500mg and abiraterone acetate tablets 250mg from Gautam Budh Nagar, India.

Fulvestrant Injection 250mg

Fulvestrant Injection 250mg
  • Fulvestrant Injection 250mg
Ask For Price
Product Price :Get Latest Price

Product Details:

TreatmentAnti cancer
Prescription/Non prescriptionPrescription
CompositionFulvestrant Injection
Dose250 mg
Packaging Size1 vial of 250mg + 5ml syringe
BrandN/a

Indications:
  • Fulvenat an anti-estrogen drug, is prescribed for the treatment of estrogen-related breast cancers. The drug inhibits the action of estrogen and prevents the growth of estrogen-dependent cancer cells. Fulvestrant is also prescribed in postmenopausal women with drug-resistant breast cancer.

Fulvenat is indicated:

As monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:
  • not previously treated with endocrine therapy, or- with disease relapse on or after adjuvant antioestrogen therapy, or disease progression on antioestrogen therapy.
  • In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.
  • In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
Request
Callback
Yes! I am Interested

Paclitaxel Nanoparticle Injection

Paclitaxel Nanoparticle Injection
  • Paclitaxel Nanoparticle Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

CompositionPaclitaxel Nanoparticle Injection
Dose100 mg
Packaging Size1 Vial
Packaging TypeBox, Bottle
Brandn/a
UsageClinical, Hospital, Personal,Commercial

Indications:
  • Paclitax NAB monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.
  • Paclitax NAB in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
  • Paclitax NAB in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Request
Callback
Yes! I am Interested

Trastuzumab for Injection 440mg/150mg

Trastuzumab  for Injection 440mg/150mg
  • Trastuzumab  for Injection 440mg/150mg
Ask For Price
Product Price :Get Latest Price

Product Details:

Packaging TypeBox
TreatmentAnti cancer
Prescription/Non prescriptionPrescription
Dose440mg/150mg
CompositionTrastuzumab for Injection
UsageClinical, Hospital, Personal,Commercial

Indications:

Breast cancer

Metastatic breast cancer

Hertraz is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer: (MBC):
  • As monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.
  • In combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.
  • In combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
  • In combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.

Early breast cancer
  • Hertraz is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).
  • Following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).
  • Following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.
  • In combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.
  • In combination with neoadjuvant chemotherapy followed by adjuvant Hertraz therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.
  • Hertraz should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

Metastatic gastric cancer
  • Hertraz in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
  • Hertraz should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.
Request
Callback
Yes! I am Interested

Nimotuzumab Injection

Nimotuzumab Injection
  • Nimotuzumab Injection
Ask For Price
Product Price :Get Latest Price

Product Details:

CompositionNimotuzumab Injection
Dose50 mg
Packaging Size4x10 ml
Packaging TypeBox
Brandn/a
UsageClinical, Hospital, Personal,Commercial

Indications:
  • Nimotuzumab is a monoclonal antibody and an endothelial growth factor receptor (EGRF) antagonist.
  • It also stimulates the immune system against the cancer cells.
  • It is a targeted therapy used for the treatment of glioma (cancer in the brain and spinal cord), cancer of the head and neck, and nasopharyngeal cancer.
  • It prevents the growth and spread of the cancer.
Request
Callback
Yes! I am Interested

Pemetrexed for Injection 500mg

Pemetrexed for Injection 500mg
  • Pemetrexed for Injection 500mg
Ask For Price
Product Price :Get Latest Price

Product Details:

TreatmentAnti cancer
Prescription/Non prescriptionPrescription
CompositionPemetrexed for Injection
Dose500 mg
Packaging SizeSingle Vial Dose
Packaging TypeBottle
UsageClinical, Hospital, Personal, Commercial

Indications:
  • Pemetrexed in combination with Cisplatin is indicated for the treatment of chemotherapy-naive patients with unresectable malignant pleural mesothelioma. Pemetrexed in combination with Cisplatin is indicated as a first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Pemetrexed is indicated as a monotherapy for the maintenance treatment of locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based therapy.
Request
Callback
Yes! I am Interested

Abiraterone Acetate Tablets 250mg

Abiraterone Acetate Tablets 250mg
  • Abiraterone Acetate Tablets 250mg
Ask For Price
Product Price :Get Latest Price

Product Details:

TreatmentAnti cancer
Prescription/Non prescriptionPrescription
CompositionAbiraterone Acetate Tablets
CategoryProstate cancer
Dose250 mg
Packaging Size120 tablets
Packaging TypeBottle,Box
UsageClinical, Hospital, Personal,Commercial

Indications:

Abiraterone acetate tablets is indicated with prednisone or prednisolone for:
  • The treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
  • The treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
  • The treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
Request
Callback
Yes! I am Interested

Sorafenib Tablets 200 mg

Sorafenib Tablets 200 mg
  • Sorafenib Tablets 200 mg
Ask For Price
Product Price :Get Latest Price

Product Details:

TreatmentAnti cancer
Prescription/Non prescriptionPrescription
CompositionSorafenib Tablets
Packaging TypeBox
Dose200 mg
Packaging Size60 tablets

Indications:
  • Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Hepatocellular carcinoma
  • Nexavar is indicated for the treatment of hepatocellular carcinoma.

Renal cell carcinoma
  • Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Differentiated thyroid carcinoma
  • Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Request
Callback
Yes! I am Interested

Sorafenib Tosylate Tablets

Sorafenib Tosylate Tablets
  • Sorafenib Tosylate Tablets
Ask For Price
Product Price :Get Latest Price

Product Details:

CompositionSorafenib Tosylate Tablets
Packaging TypeBottle
UsageClinical, Hospital, Personal,Commercial
Dose200 mg
Packaging Size120 tablets

Indications:
  • Sorafenib is used to treat kidney, liver, and thyroid cancer. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Hepatocellular carcinoma
  • Sorafenib is indicated for the treatment of hepatocellular carcinoma.

Renal cell carcinoma
  • Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Differentiated thyroid carcinoma
  • Sorafenib is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Request
Callback
Yes! I am Interested

Erlotinib Tablets 100mg/150mg

Erlotinib Tablets 100mg/150mg
  • Erlotinib Tablets 100mg/150mg
Ask For Price
Product Price :Get Latest Price

Product Details:

TreatmentAnti cancer
Prescription/Non prescriptionPrescription
CompositionErlotinib Tablets
Dose100 mg/150 mg
Packaging Size30 tablets
Packaging TypeBottle

Indications:
  • Erlotinib is Non-Small-Cell Lung Cancer (NSCLC). Erlotinib is indicated as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
Request
Callback
Yes! I am Interested

Filgrastim Injection 75/150 mcg

Filgrastim Injection 75/150 mcg
  • Filgrastim Injection 75/150 mcg
Ask For Price
Product Price :Get Latest Price

Product Details:

ManufacturerFlorencia
Prescription/Non prescriptionPrescription
BrandN/a
Packaging Size1 ml
Dose/Strength75/150 mcg
UsageClinical, Hospital, Personal,Commercial
Pack TypeBox
CompositionFilgrastim Injection

Indications:
  • Filgrastim injection is used to treat neutropenia (low white blood cells) that is caused by cancer medicines. It is a synthetic (man-made) form of a substance that is naturally produced in your body called a colony stimulating factor. Filgrastim helps the bone marrow to make new white blood cells.
  • When certain cancer medicines are used to fight cancer cells, they also affect the white blood cells that fight infections. Filgrastim is used to prevent or reduce the risk of infection while you are being treated with cancer medicines. This medicine is also used to help the bone marrow recover after a bone marrow transplantation, for a process called peripheral blood progenitor cell collection in cancer patients, and to improve survival in cancer patients who have been exposed to radiation.
Request
Callback
Yes! I am Interested
X

Explore More Product

View All Product


Reach Us
Reshma Mishra (CEO)
Florencia Healthcare
512, 5th Floor, The I-thum, Tower-B, Plot no. A-40, Sector-62, Noida
Gautam Budh Nagar - 201301, Uttar Pradesh, India


Call Us


Send E-mail